Antiarrhythmic Drugs

Correct Answer

C — Beta-blockers, non-dihydropyridine calcium channel blockers, and digoxin

Rationale

Rate control in atrial fibrillation targets the atrioventricular node to limit how many atrial impulses reach the ventricles. The three drug classes used for this purpose are beta-blockers (which reduce sympathetic atrioventricular nodal drive), non-dihydropyridine calcium channel blockers such as verapamil and diltiazem (which directly block nodal calcium channels), and digoxin (which enhances vagal tone). Flecainide, propafenone, and sotalol are rhythm control agents. Amiodarone, dofetilide, and ibutilide are also rhythm control agents. Quinidine, procainamide, and disopyramide are Class Ia sodium channel blockers used historically for rhythm control.

Correct Answer

A — Flecainide and propafenone

Rationale

Flecainide and propafenone (Class Ic sodium channel blockers) are the preferred rhythm control agents for atrial fibrillation in patients with no structural heart disease. Their proarrhythmic risk is acceptably low in a structurally normal heart, and they are effective for maintaining sinus rhythm. They are contraindicated in structural heart disease because their slow unbinding kinetics cause dangerous conduction slowing in fibrotic or ischemic myocardium, as demonstrated in the Cardiac Arrhythmia Suppression Trial. Amiodarone and dofetilide are used when structural heart disease or heart failure with reduced ejection fraction is present. Quinidine and disopyramide are Class Ia agents with higher toxicity and are rarely used today. Lidocaine and mexiletine are for ventricular arrhythmias, not rhythm control of atrial fibrillation.

Correct Answer

D — Amiodarone and dofetilide

Rationale

Amiodarone and dofetilide are the two rhythm control agents proven safe in structural heart disease and heart failure with reduced ejection fraction. Amiodarone has multi-class activity and mild hemodynamic effects that are well tolerated even in reduced ventricular function. Dofetilide is a pure Class Three potassium channel blocker with no negative inotropic effect, and clinical trials have confirmed its safety in heart failure with reduced ejection fraction. Flecainide and propafenone are contraindicated in structural heart disease due to proarrhythmic risk. Sotalol carries a moderate risk of torsades de pointes and is reserved for patients without significant structural disease. Dronedarone is contraindicated in heart failure with reduced ejection fraction due to increased mortality. Verapamil and diltiazem are rate control — not rhythm control — agents, and both are contraindicated in heart failure with reduced ejection fraction.

Correct Answer

B — Rivaroxaban

Rationale

Rivaroxaban is a direct oral anticoagulant — specifically a direct factor Xa inhibitor — classified and approved for stroke prevention in non-valvular atrial fibrillation. Direct oral anticoagulants also include apixaban, dabigatran, and edoxaban. Warfarin is a vitamin K antagonist, not a direct oral anticoagulant. Heparin is a parenteral anticoagulant. Aspirin is an antiplatelet agent and is not an anticoagulant.

Correct Answer

C — Rhythm control agent appropriate for patients with no structural heart disease or significant coronary artery disease

Rationale

Flecainide is classified as a rhythm control agent for atrial fibrillation, appropriate only in patients without significant structural heart disease or coronary artery disease. Its Class Ic sodium channel blocking properties create proarrhythmic risk in fibrotic or ischemic myocardium, as demonstrated by the Cardiac Arrhythmia Suppression Trial. It is not a rate control agent, not an anticoagulant, and is contraindicated in heart failure with reduced ejection fraction.

Correct Answer

A — Sotalol

Rationale

Sotalol is classified as having both Class Two and Class Three activity. Its beta-blocking (Class Two) component slows heart rate and atrioventricular nodal conduction, while its potassium channel blocking (Class Three) component prolongs the action potential duration and effective refractory period. Amiodarone and dronedarone have multi-class activity spanning Classes One through Four. Dofetilide is a pure Class Three potassium channel blocker with no beta-blocking activity.

Correct Answer

D — Rate control and rhythm control produced equivalent overall mortality, meaning the choice between strategies should be guided by symptoms, patient preference, and clinical context

Rationale

The AFFIRM trial (Atrial Fibrillation Follow-up Investigation of Rhythm Management), published in 2002, randomized over 4,000 patients with atrial fibrillation to rate control versus rhythm control and found no difference in overall mortality between the two strategies. The rhythm control arm was not superior despite achieving sinus rhythm more often, partly because the antiarrhythmic drugs used carried their own toxicity burden that offset the potential benefits of sinus rhythm. AFFIRM established that rate control is an acceptable long-term strategy — particularly in older or less symptomatic patients — and shifted the default approach for many clinicians toward rate control first. It did not show that rhythm control should be avoided; rather, it showed that the strategy choice should be individualized. Both arms maintained anticoagulation throughout the trial, confirming that anticoagulation decisions should not be based on rhythm status alone.

Correct Answer

B — EAST-AFNET 4 found that early rhythm control within one year of atrial fibrillation diagnosis reduced cardiovascular outcomes in selected patients, supporting earlier rhythm control in appropriate candidates

Rationale

EAST-AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial), published in 2020, randomized patients with recently diagnosed atrial fibrillation to early rhythm control (within approximately one year of diagnosis) versus usual care (predominantly rate control). Early rhythm control reduced the composite primary outcome of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome. This finding challenged the AFFIRM-era assumption that rate control was always an acceptable default, suggesting that rhythm control initiated early in the disease course — before atrial remodeling becomes irreversible — may offer additional benefit in selected patients with cardiovascular risk factors. EAST-AFNET 4 did not specify which antiarrhythmic to use, and most patients also had catheter ablation available as part of rhythm control. The finding shifted practice toward earlier consideration of rhythm control in patients with recently diagnosed atrial fibrillation and cardiovascular comorbidities.

Correct Answer

A — Non-dihydropyridine calcium channel blockers have a negative inotropic effect that can worsen ventricular function in heart failure with reduced ejection fraction, whereas beta-blockers have proven long-term mortality benefit in this population

Rationale

Verapamil and diltiazem block L-type calcium channels throughout the myocardium, reducing contractility in addition to slowing atrioventricular nodal conduction. In heart failure with reduced ejection fraction, where the ventricle is already contracting at the limits of its reserve, this negative inotropic effect can precipitate acute decompensation — making these drugs contraindicated in that setting. Beta-blockers, when used carefully in stable (not acutely decompensated) heart failure with reduced ejection fraction, provide both rate control and proven long-term mortality benefit through suppression of adverse sympathetic remodeling. Carvedilol, metoprolol succinate, and bisoprolol all reduce sudden cardiac death and all-cause mortality in heart failure with reduced ejection fraction. If beta-blockers are contraindicated, digoxin is the preferred alternative for rate control in this population.

Correct Answer

C — The patient must have no structural heart disease, and a pre-dose atrioventricular nodal blocker must be taken to prevent rapid ventricular conduction if atrial flutter develops

Rationale

Two requirements govern the pill-in-pocket strategy with flecainide. First, the patient must have no structural heart disease — flecainide is proarrhythmic in structurally abnormal myocardium, and the Cardiac Arrhythmia Suppression Trial demonstrated its lethal potential in post-infarction patients. Second, a beta-blocker or non-dihydropyridine calcium channel blocker must be taken before the flecainide dose. Flecainide slows intra-atrial conduction and can organize atrial fibrillation into atrial flutter cycling at 200 to 250 beats per minute. If the atrioventricular node transmits every atrial flutter impulse at 1:1, the ventricular rate can exceed 200 beats per minute — a hemodynamically dangerous scenario. The pre-dose nodal blocker ensures the atrioventricular node will filter most of these impulses. The same two requirements apply to propafenone used in this strategy. The strategy should be tested in hospital before outpatient use.

Correct Answer

D — Cardioversion produces atrial stunning — a period of reduced atrial mechanical function — during which organized atrial contraction is impaired and new thrombus can form despite restoration of electrical sinus rhythm

Rationale

Atrial stunning refers to a period of reduced or absent atrial mechanical contraction that follows cardioversion, even when electrical sinus rhythm has been successfully restored. Despite the atria receiving and transmitting normal electrical impulses, the atrial myocardium — particularly the left atrial appendage — contracts poorly for days to weeks after cardioversion. During this stunned period, blood pools in the left atrial appendage with reduced clearance, creating conditions favorable for thrombus formation. A stroke can therefore occur after cardioversion even if no thrombus was present before the procedure. This is why four weeks of anticoagulation are mandated after cardioversion regardless of pre-cardioversion strategy. Atrial stunning is more prolonged after longer durations of atrial fibrillation and in patients with enlarged atria or reduced ventricular function.

Correct Answer

B — Digoxin's rate control depends on enhanced vagal tone, which is suppressed by sympathetic activation during exertion or stress, allowing the ventricular rate to escape control at the times it matters most

Rationale

Digoxin slows the ventricular rate in atrial fibrillation through indirect vagotonic enhancement of atrioventricular nodal refractoriness rather than by directly blocking nodal channels. Vagal tone is physiologically reduced during physical activity, emotional stress, fever, or sympathomimetic drug use — precisely when a patient is most likely to have elevated catecholamines and least able to tolerate a fast ventricular rate. During these states, sympathetic activation overrides vagal tone, and digoxin loses much of its rate-control effect. Beta-blockers and non-dihydropyridine calcium channel blockers block the atrioventricular node through direct mechanisms independent of the autonomic balance, so they maintain rate control during activity. Digoxin remains useful in sedentary patients, in heart failure (where beta-blockers may not be tolerated), or in combination with other rate control agents. It is not used for rhythm control of atrial fibrillation.

Correct Answer

A — Amiodarone is safe in structural heart disease and heart failure with reduced ejection fraction, whereas the Class Ic agents are contraindicated and sotalol and dronedarone carry unacceptable risks in this substrate

Rationale

The rhythm control drug selection for atrial fibrillation is determined primarily by the underlying cardiac substrate. In a patient with prior myocardial infarction and borderline reduced ejection fraction: Class Ic agents (flecainide, propafenone) are absolutely contraindicated due to their proarrhythmic risk in structurally abnormal myocardium. Sotalol carries meaningful torsades de pointes risk and is not preferred in significant structural disease. Dronedarone is contraindicated in heart failure with reduced ejection fraction. Amiodarone and dofetilide are the two agents with proven safety in this substrate. Amiodarone is generally the most widely used in practice because of its broad efficacy and multi-class activity, though its long-term toxicity profile (pulmonary, thyroid, hepatic, corneal) requires surveillance. Amiodarone does prolong the QT interval markedly, but its paradoxically low torsades de pointes rate — attributed to its multi-channel activity — makes it the preferred choice despite QT prolongation.

Correct Answer

C — Class Ic agents such as flecainide or propafenone, which are appropriate for rhythm control in the absence of structural heart disease

Rationale

In a patient with atrial fibrillation and no structural heart disease, Class Ic agents — flecainide or propafenone — are the appropriate pharmacological rhythm control option. They are effective and well tolerated in structurally normal myocardium. Class Three agents such as amiodarone and dofetilide are appropriate when structural heart disease or heart failure with reduced ejection fraction is present. Beta-blockers are used for rate control, not rhythm control as primary agents. Calcium channel blockers (Class Four) slow the ventricular rate but do not convert atrial fibrillation to sinus rhythm.

Correct Answer

D — Flecainide or propafenone taken with a beta-blocker or non-dihydropyridine calcium channel blocker — the nodal blocker prevents rapid ventricular conduction if atrial flutter develops before cardioversion

Rationale

For the pill-in-pocket strategy in a patient with no structural heart disease, flecainide or propafenone is the agent of choice because both are effective at pharmacological cardioversion of recent-onset atrial fibrillation and are safe in the absence of structural disease. However, both drugs slow intra-atrial conduction, which can organize atrial fibrillation into atrial flutter before restoring sinus rhythm. Atrial flutter cycles at approximately 200 to 250 beats per minute, and if the atrioventricular node conducts all impulses with 1:1 conduction, the ventricular rate can reach dangerous levels. Co-administration of a beta-blocker or non-dihydropyridine calcium channel blocker slows atrioventricular nodal conduction, preventing this complication. Amiodarone is not appropriate for pill-in-pocket use given its long half-life and toxicity profile. Dofetilide requires in-hospital initiation and is not used as a pill-in-pocket agent. Sotalol's beta-blocking activity provides some nodal protection but sotalol itself requires in-hospital initiation and is not typically used as a pill-in-pocket cardioversion agent.

Correct Answer

B — Amiodarone is appropriate; flecainide is contraindicated because its slow sodium channel unbinding creates proarrhythmic conduction slowing in the fibrotic, structurally abnormal myocardium present in heart failure with reduced ejection fraction

Rationale

In heart failure with reduced ejection fraction, myocardial fibrosis and adverse remodeling create heterogeneous conduction throughout the ventricles. Class Ic agents such as flecainide unbind from sodium channels very slowly, causing additional conduction slowing that converts areas of already-impaired conduction into areas of complete block. This creates the substrate for re-entry circuits and potentially lethal ventricular arrhythmias — the mechanism demonstrated in the Cardiac Arrhythmia Suppression Trial. Flecainide does not prolong the QT interval; its contraindication in structural heart disease is entirely proarrhythmic through conduction slowing, not QT prolongation. Amiodarone is safe in heart failure with reduced ejection fraction and is the most commonly used rhythm control agent in this population. Dofetilide is also safe and is a reasonable alternative. Sotalol is generally avoided in significant structural heart disease due to its torsades de pointes risk and is contraindicated in heart failure with reduced ejection fraction. Amiodarone is not contraindicated in heart failure with reduced ejection fraction; its mild negative inotropic effect is hemodynamically well tolerated.

Correct Answer

A — Cardioversion produces atrial stunning — temporary impairment of atrial mechanical function — during which the left atrial appendage contracts poorly and new thrombus can form despite restoration of electrical sinus rhythm

Rationale

Atrial stunning describes the period after cardioversion during which the atria — particularly the left atrial appendage — have recovered electrically (they receive and transmit sinus impulses normally) but have not yet recovered mechanically. The atrial myocardium contracts weakly or inconsistently for days to weeks post-cardioversion, creating conditions favorable for thrombus formation in the left atrial appendage. Stroke can therefore occur after cardioversion even when no thrombus was detected before the procedure. This is why four weeks of anticoagulation are mandated after all cardioversions, regardless of pre-cardioversion transesophageal echocardiogram findings or CHA2DS2-VASc score. Atrial stunning is more pronounced after longer durations of atrial fibrillation and in patients with structural heart disease or enlarged left atria. The transesophageal echocardiogram strategy confirms no pre-existing thrombus, but it cannot prevent stunning-related thrombus formation after cardioversion.

Correct Answer

C — The AFFIRM trial demonstrated equivalent mortality between rate control and rhythm control, supporting rate control as a reasonable initial strategy — particularly in older or mildly symptomatic patients where antiarrhythmic drug toxicity may outweigh the benefit of restoring sinus rhythm

Rationale

The AFFIRM trial established that rate control and rhythm control produce equivalent overall mortality in patients with atrial fibrillation. This finding legitimized rate control as a primary long-term strategy rather than a stopgap until sinus rhythm could be restored. For older patients with mild or well-tolerated symptoms, rate control is particularly appropriate because antiarrhythmic drug toxicity accumulates with long-term use — amiodarone's pulmonary, thyroid, and hepatic effects; sotalol's torsades de pointes risk in the presence of renal impairment — and because older patients are more susceptible to these harms. The EAST-AFNET 4 trial suggested benefit from early rhythm control in selected patients with cardiovascular risk factors and recently diagnosed atrial fibrillation, but this finding is most applicable to patients diagnosed within one year — not a patient with long-standing atrial fibrillation and mild symptoms. Anticoagulation decisions in either strategy should be based on CHA2DS2-VASc score, not on whether sinus rhythm is maintained.